49 results on '"Cassady, Kaniel"'
Search Results
2. Optimizing the therapeutic window of sirolimus by monitoring blood concentration for the treatment of immune thrombocytopenia
3. Donor T cell STAT3 deficiency enables tissue PD-L1–dependent prevention of graft-versus-host disease while preserving graft-versus-leukemia activity
4. Azacitidine and lenalidomide combination: a novel relapse prophylaxis regimen after allogeneic hematopoietic stem-cell transplantation in patients with acute myeloid leukemia
5. Blockade of trans PD-L1 interaction with CD80 augments antitumor immunity
6. Supplemental Materials from Increased Expression of System xc− in Glioblastoma Confers an Altered Metabolic State and Temozolomide Resistance
7. Data from Increased Expression of System xc− in Glioblastoma Confers an Altered Metabolic State and Temozolomide Resistance
8. Supplemental Figures 1-5 from Increased Expression of System xc− in Glioblastoma Confers an Altered Metabolic State and Temozolomide Resistance
9. Optimizing the therapeutic window of sirolimus by monitoring blood concentration for the treatment of immune thrombocytopenia.
10. Antibodies from donor B cells perpetuate cutaneous chronic graft-versus-host disease in mice
11. MHC-mismatched mixed chimerism augments thymic regulatory T-cell production and prevents relapse of EAE in mice
12. Progress on the efficacy and potential mechanisms of rapamycin in the treatment of immune thrombocytopenia
13. PD-L1 interacts with CD80 to regulate graft-versusleukemia activity of donor [CD8.sup.+] T cells
14. Clinical characteristics in immune thrombocytopenia patients after COVID-19 vaccination
15. Administration of Anti-CD20 mAb Is Highly Effective in Preventing but Ineffective in Treating Chronic Graft-Versus-Host Disease While Preserving Strong Graft-Versus-Leukemia Effects
16. Depletion of Host CCR7+ Dendritic Cells Prevented Donor T Cell Tissue Tropism in Anti-CD3–Conditioned Recipients
17. Pretransplantation minimal residual disease monitoring by multiparameter flow cytometry predicts outcomes of AML patients receiving allogeneic hematopoietic stem cell transplantation
18. microRNA-142 guards against autoimmunity by controlling Treg cell homeostasis and function
19. The Addition of Sirolimus to GVHD Prophylaxis After Allogeneic Hematopoietic Stem Cell Transplantation: A Meta-Analysis of Efficacy and Safety
20. Case Report: PD-1 Blockade Combined Autologous Hematopoietic Stem Cell Transplantation With Modified BEAM Regimen Containing High-Dose Cytarabine to Treat R/R Hodgkin's Lymphoma
21. Abstract 3180: Blockade of PD-L1 interaction with CD80in transaugments anti-tumor immunity by increasing NOS2 in tumor-associated macrophages
22. The Role of mTOR Inhibitors in Hematologic Disease: From Bench to Bedside
23. Effect of rhG-CSF Combined With Decitabine Prophylaxis on Relapse of Patients With High-Risk MRD-Negative AML After HSCT: An Open-Label, Multicenter, Randomized Controlled Trial
24. microRNA-142 guards against autoimmunity by controlling Treg cell homeostasis and function.
25. Blockade of CD80 interaction with PD-L1 between T and tumor cells augments effector T expansion and tumor immunity in a PD-1-dependent manner
26. Sirolimus as Rescue Therapy for Refractory/Relapsed Immune Thrombocytopenia: Results of a Single-Center, Prospective, Single-Arm Study
27. TET2 Function in Hematopoietic Malignancies, Immune Regulation, and DNA Repair
28. Effect of rhG-CSF Combined with Decitabine Prophylaxis on Relapse in High-Risk Acute Myeloid Leukemia Patients after Hematopoietic Stem Cell Transplantation: An Open-Label, Multicenter, Randomized, Controlled, Phase 2 Trial
29. Regulation of GVHD and GVL Activity via PD-L1 Interaction With PD-1 and CD80
30. MicroRNA-142 guards against autoimmunity by controlling Treg cell development and function
31. Increased expression of system xc− in glioblastoma confers an altered metabolism and chemoresistance
32. PD-L1/CD80 interaction differentially regulates CD8+ T cell metabolism, survival and GVHD capacity in the presence or absence of PD-1
33. PD-L1 interacts with CD80 to regulate graft-versus-leukemia activity of donor CD8+ T cells
34. Increased Expression of System xc− in Glioblastoma Confers an Altered Metabolic State and Temozolomide Resistance
35. Blockade of PD-L1/CD80 Interactions Augments Function of Activated Donor T Cells Results in Augmenting Gvhd Induced By Donor Naïve CD8 +t Cells and GVL Effect Mediated By Donor Memory CD8 +T Cells
36. Transient depletion of donor CD4+ T cells early after HCT allows recipient tissue PD-L1 to tolerize infiltrating CD8+ T cells and to prevent acute GVHD while preserving GVL effect
37. Host Tissue PD-L1 Separates GVL Effect from Gvhd after Temporary Depletion of Donor CD4+ T Cells Early after HCT
38. PD-L1/CD80 and PD-L1/PD-1 Signaling Reciprocally Regulate Alloreactive CD8+ T Cell Glycolysis, Proliferation, Apoptosis and Gvhd-Inducing Capacity
39. B7H1/CD80 Interaction Augments PD-1–Dependent T Cell Apoptosis and Ameliorates Graft-versus-Host Disease
40. B7H1/B7.1 Interaction Alleviate Acute Gvhd in a PD-1 Dependent Manner
41. MHC-mismatched mixed chimerism augments thymic regulatory T-cell production and prevents relapse of EAE in mice.
42. B7H1/CD80 Interaction Augments PD-1-Dependent T Cell Apoptosis and Ameliorates Graft-versus-Host Disease.
43. Pretransplantation minimal residual disease monitoring by multiparameter flow cytometry predicts outcomes of AML patients receiving allogeneic hematopoietic stem cell transplantation.
44. Donor T cell STAT3 deficiency enables tissue PD-L1– dependent prevention of graft-versus-host disease while preserving graft-versus-leukemia activity.
45. PD-L1/CD80 and PD-L1/PD-1 Signaling Reciprocally Regulate Alloreactive CD8+T Cell Glycolysis, Proliferation, Apoptosis and Gvhd-Inducing Capacity
46. Host Tissue PD-L1 Separates GVL Effect from Gvhd after Temporary Depletion of Donor CD4+T Cells Early after HCT
47. PD-L1 interacts with CD80 to regulate graft-versus-leukemia activity of donor CD8+ T cells.
48. Antibodies from donor B cells perpetuate cutaneous chronic graft-versus-host disease in mice.
49. Linvoseltamab for Treatment of Relapsed/Refractory Multiple Myeloma.
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.